Related Experiment Video
Updated: Jun 23, 2025
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.5K
Semaglutide and heart failure: Updated meta-analysis
Leandro Barbagelata1, Walter Masson1, Martín Lobo2
1Department of Cardiology. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Current Problems in Cardiology
|June 22, 2024
Summary
Semaglutide use significantly reduced the risk of heart failure (HF) events in patients. This meta-analysis confirms semaglutide
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Heart failure (HF) presents a significant global health burden, impacting mortality and healthcare costs.
- Glucagon-like peptide-1 receptor agonists (GLP-1RA) show potential in managing HF, but their exact effects require clarification.
Purpose of the Study:
- To evaluate the impact of semaglutide on heart failure-related outcomes.
- To synthesize evidence on semaglutide's efficacy in HF management.
Main Methods:
- A meta-analysis was conducted following PRISMA guidelines.
- Included randomized clinical trials and observational studies with ≥ 6 months follow-up.
- A random-effects model was employed for data synthesis.
Main Results:
- Six RCTs (n=28,762) and two observational studies were analyzed.
- Semaglutide use was associated with a reduced risk of HF events (OR: 0.74; 95% CI: 0.58-0.94).
- Analysis indicated no publication bias, and sensitivity analysis confirmed result robustness.
Conclusions:
- Semaglutide use is linked to a decrease in heart failure clinical events.
- Further research is needed to explore semaglutide's effects across diverse HF patient subgroups.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K